Product
MDG1011
1 clinical trial
4 indications
Indication
SafetyIndication
TolerabilityIndication
FeasibilityIndication
Efficacy of TreatmentClinical trial
A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial With Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects With High Risk Myeloid and Lymphoid NeoplasmsStatus: Terminated, Estimated PCD: 2022-06-28